Current Highlight from August 22, 2014
Bovine Intestinal Bacteria Degrade and Inactivate Ceftiofur
NCTR scientists have shown that ceftiofur—a cephalosporin antimicrobial drug that is approved for veterinary use to treat respiratory disease in cattle, swine, horses, and sheep—is rapidly degraded by bovine intestinal bacteria using a metallo-b-lactamase. Ceftiofur is structurally similar to the human-use cephalosporin ceftriaxone, and concerns have been raised that use of ceftiofur may adversely impact the effectiveness of other related cephalosporins through the development of antimicrobial resistance. These results show that bacteria present in the naïve bovine gut are capable of degrading and enzymatically inactivating cephalosporin antimicrobials and reducing environmental exposure to these antimicrobials. This study is available online atVeterinary Microbiology
.
.
For additional information, please contact Bruce Erickson, Ph.D., Staff Fellow, Division of Microbiology, FDA/NCTR.
NCTR Research Highlights Archives
- 2014-NCTR Research Highlights
- 2013-NCTR Research Highlights [ARCHIVED]
- 2012-NCTR Research Highlights
- 2011-NCTR Research Highlights [ARCHIVED]
- 2010-NCTR Research Highlights [ARCHIVED]
- 2009-NCTR Research Highlights
- 2008-NCTR Research Highlights [ARCHIVED]
- 2007-NCTR Research Highlights [ARCHIVED]
- 2006-NCTR Research Highlights [ARCHIVED]
Contact FDA
870-543-7000
National Center for Toxicological Research
Food and Drug Administration
3900 NCTR Road
Jefferson, AR 72079
.png)
No hay comentarios:
Publicar un comentario